FDA approval of milsaperidone puts Vanda Pharmaceuticals into crowded bipolar I disorder and schizophrenia markets
FDA approves milsaperidone for bipolar I disorder and schizophrenia. Explore what this means for psychiatry, competition, and Vanda Pharmaceuticals’ strategy.